about
TAp63 prevents premature aging by promoting adult stem cell maintenanceMolecular cancer prevention: Current status and future directionsMutational landscape of aggressive cutaneous squamous cell carcinomaSafety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.TCF7L1 promotes skin tumorigenesis independently of β-catenin through induction of LCN2.Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression.ARF mutation accelerates pituitary tumor development in Rb+/- mice.Drug safety evaluation of vemurafenib in the treatment of melanoma.IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.Roles of the immune system in skin cancer.The genetics of skin cancer.ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates.Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.MELPREDICT: a logistic regression model to estimate CDKN2A carrier probabilityLues maligna in early HIV infection case report and review of the literature.Induced multipotency in adult keratinocytes through down-regulation of ΔNp63 or DGCR8.Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD.Optimized lysis buffer reagents for solubilization and preservation of proteins from cells and tissues.Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicityMEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.Assessing the treatment of nonmelanoma skin cancers.Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine.An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.A reagent to facilitate protein recovery from cells and tissues.Precision medicine.Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes.Collagenous vasculopathy: a report of three cases.Dynamic gene expression analysis links melanocyte growth arrest with nevogenesis.Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.Differential T-cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals.Eruptive squamous cell carcinomas after vemurafenib therapy.Analysis of Cell Mechanics in Single Vinculin-Deficient Cells Using a Magnetic TweezerAPOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosaARF is not required for apoptosis in Rb mutant mouse embryosPrimer on the human genome
P50
Q24618256-BB103F3F-140D-4B8F-8366-483DF0FE854DQ26797207-3AEB173B-837B-4554-9B99-30DF1C92B86EQ27853082-1F112023-AC74-4E4B-8EED-C91264CAAA80Q33418964-D527C8C3-7B8E-4D3B-8B79-69377154FBCEQ33708229-C756F249-DCED-45E7-87C0-FA0FAE13615CQ33806005-47128990-AE34-4476-A3CA-E171CD1FF0BCQ34430199-06DB5A49-B5DE-4251-9221-8AACA6D5825AQ34653547-3D127681-B1B5-406A-8E71-5DDE1C410E69Q35032609-A3F5B226-FE72-498E-A3CE-2484A3B81C7CQ35403714-578CE844-1317-4A94-8FE9-45769C9501D8Q35910656-424DDAAE-2F8D-47CC-808E-0B926FD2881AQ36051831-38FDF90E-7773-41EC-9EB8-894E8CB57A8FQ36116513-860C8357-8389-4894-BBA8-5D95C1F0B187Q36342842-4196B428-BA3F-4AB8-9BFE-127E5852195AQ36930086-AED1CA8E-A24A-4C47-A6B2-7F8492D61120Q37489451-81A45354-BB09-482B-8B65-F16417BB6341Q37571123-50545B92-C78E-4B3F-B57F-1F1BA3708B30Q38123513-2FDA97B3-5AF0-481D-9F79-8CEA913E98D1Q38782628-B88B74E5-8637-4FD2-9914-66AF9C342D0BQ39068901-FDB00293-C935-4562-9328-2816833AD349Q39982138-F6A7EE62-887C-4910-B589-1A154894ABBEQ41195479-F14CF939-9A89-41EC-A4F8-F0B756DB8846Q41417492-5C8D90B4-CB11-4100-81C9-C33E182753D3Q42074554-C8786872-1D3D-41AD-8E17-FE41B9EA051BQ42488432-E7FFB29C-924B-4F06-8099-CE439881753BQ42553470-411D7285-23E1-42FD-9FC7-1EEAA63C70E6Q42797525-0BD4863E-6DFB-479C-92E3-41DF8873C9BBQ46665465-543E2B3F-0504-43ED-88D8-D98172ECB528Q46745638-82244705-4044-4BB2-88D8-C5A3E5DC29A7Q46857395-FAF68FE1-371F-4606-859F-8F06758725AFQ47406043-26142904-1510-400B-9281-E3D7192CF2E9Q50646549-052D50AF-DCE8-4633-BB6D-255915D6656EQ51776779-456AA56D-F257-4D2E-983E-BFA8C8FDA2C9Q52607328-249B9842-B964-494F-ABFF-659BF3B70972Q53308170-CA196C73-6E1A-43B6-98A8-C1F4451A47A2Q54730758-DD6328BC-2212-43A1-B748-9ABD185B169FQ58346989-F53164A0-CB6C-4ACB-995E-E2E585323C89Q63804811-125860BF-8CE7-4AD8-9FD5-899B686DFB80Q77568660-A679057D-B1F9-49FD-8BA5-D71E557C9663Q80166563-BB3974D1-4A38-421A-989C-4A9DE7A1F1AB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kenneth Y. Tsai
@ast
Kenneth Y. Tsai
@en
Kenneth Y. Tsai
@es
Kenneth Y. Tsai
@nl
Kenneth Y. Tsai
@sl
type
label
Kenneth Y. Tsai
@ast
Kenneth Y. Tsai
@en
Kenneth Y. Tsai
@es
Kenneth Y. Tsai
@nl
Kenneth Y. Tsai
@sl
prefLabel
Kenneth Y. Tsai
@ast
Kenneth Y. Tsai
@en
Kenneth Y. Tsai
@es
Kenneth Y. Tsai
@nl
Kenneth Y. Tsai
@sl
P106
P1153
7201565756
P21
P31
P496
0000-0001-5325-212X